More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
“This type of screening could be used to identify individuals who would benefit from statin medication but are currently untreated," one specialist said. The full analysis will be presented at RSNA 2022 in Chicago.
The use of NSAIDS such as ibuprofen and naproxen might not have the desired effect patients are seeking when it comes to joint pain, according to new findings to be presented at RSNA 2022.
VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition.
There are limited data to determine whether pancreatitis in COVID patients is the result of a stress response triggered by severe illness or by direct damage to the β-cell structure and function.
